Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial

被引：6

作者：

Groen, Kaz ^{[1
,2
]}

Stege, Claudia A. M. ^{[1
,2
]}

Nasserinejad, Kazem ^{[3
,4
]}

de Heer, Koen ^{[5
]}

van Kampen, Roel J. W. ^{[6
]}

Leys, Rineke B. L. ^{[7
]}

Thielen, Noortje ^{[8
]}

Westerman, Matthijs ^{[9
]}

Wu, Ka-Lung ^{[10
]}

Ludwig, Inge ^{[11
]}

Issa, Djamila E. ^{[12
]}

Velders, Gerjo A. ^{[13
]}

Vekemans, Marie-Christiane ^{[14
]}

Timmers, Gert-Jan ^{[15
]}

de Boer, Fransien ^{[16
]}

Tick, Lidwine W. ^{[17
]}

Verbrugge, Annelies ^{[3
]}

Buitenhuis, Danny ^{[3
]}

Cunha, Sonia M. ^{[3
]}

van der Spek, Ellen ^{[18
]}

de Waal, Esther G. M. ^{[19
]}

Sohne, Maaike ^{[20
]}

Sonneveld, Pieter ^{[21
]}

Nijhof, Inger S. ^{[20
]}

Klein, Saskia K. ^{[22
,23
]}

van der Donk, Niels W. C. J. ^{[1
,2
]}

Levin, Mark-David ^{[24
]}

Ypma, Paula F. ^{[25
]}

Zweegman, Sonja ^{[1
,2
,26
]}

机构：

[1] Vrije Univ Amsterdam, Dept Hematol, Amsterdam UMC, Amsterdam, Netherlands

[2] Canc Ctr Amsterdam, Treatment & Qual Life, Amsterdam, Netherlands

[3] Erasmus MC Canc Inst, HOVON Data Ctr, Dept Hematol, Rotterdam, Netherlands

[4] Cytel Inc, Therapeut Dev Team, Innovat Stat Consulting, Waltham, MA USA

[5] Flevoziekenhuis, Dept Internal Med, Almere, Netherlands

[6] Zuyderland Hosp, Dept Internal Med, Sittard Geleen, Netherlands

[7] Maasstad Hosp, Dept Internal Med, Rotterdam, Netherlands

[8] Diakonessen Hosp, Dept Internal Med, Utrecht, Netherlands

[9] Northwest Clin, Dept Internal Med, Alkmaar, Netherlands

[10] ZNA Stuivenberg, Dept Hematol, Antwerp, Belgium

[11] Ziekenhuis Bernhoven, Dept Internal Med, Uden, Netherlands

[12] Jeroen Bosch Hosp, Dept Internal Med, Den Bosch, Netherlands

[13] Gelderse Vallei, Dept Internal Med, Ede, Netherlands

[14] UCL, Dept Hematol, Clin Univ St Luc, Brussels, Belgium

[15] Amstelland Hosp, Dept Internal Med, Amstelveen, Netherlands

[16] Ikazia Hosp, Dept Internal Med, Rotterdam, Netherlands

[17] Maxima Med Ctr, Dept Internal Med, Eindhoven, Netherlands

[18] Rijnstate Hosp, Dept Internal Med, Arnhem, Netherlands

[19] Med Ctr Leeuwarden, Dept Internal Med, Leeuwarden, Netherlands

[20] Antonius Ziekenhuis, Dept Internal Med, Nieuwegein, Netherlands

[21] Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[22] Meander Med Ctr, Dept Internal Med, Amersfoort, Netherlands

[23] Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands

[24] Albert Schweitzer Hosp, Dept Internal Med, Dordrecht, Netherlands

[25] Haga Hosp, Dept Internal Med, The Hague, Netherlands

[26] Dept Hematol, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands

来源：

ECLINICALMEDICINE | 2023年 / 63卷

关键词：

Multiple myeloma; Elderly; Daratumumab; Ixazomib; Intermediate-fit; IMWG frailty index; STEM-CELL TRANSPLANTATION; ORAL IXAZOMIB; LENALIDOMIDE; MAINTENANCE; BORTEZOMIB; SURVIVAL; THALIDOMIDE; PREDNISONE; MELPHALAN; CONSENSUS;

D O I：

10.1016/j.eclinm.2023.102167

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background The outcome of non-transplant eligible newly diagnosed multiple myeloma (NDMM) patients is heterogeneous, partly depending on frailty level. The aim of this study was to prospectively investigate the efficacy and safety of Ixazomib-Daratumumab-low-dose dexamethasone (Ixa-Dara-dex) in NDMM intermediate-fit patients. Methods In this phase II multicenter HOVON-143 study, IMWG Frailty index based intermediate-fit patients, were treated with 9 induction cycles of Ixa-Dara-dex, followed by maintenance with ID for a maximum of 2 years. The primary endpoint was overall response rate on induction treatment. Patients were included from October 2017 until May 2019. Trial Registration Number: NTR6297. Findings Sixty-five patients were included. Induction therapy resulted in an overall response rate of 71%. Early mortality was 1.5%. At a median follow-up of 41.0 months, median progression-free survival (PFS) was 18.2 months and 3-year overall survival 83%. Discontinuation of therapy occurred in 77% of patients, 49% due to progression, 9% due to toxicity, 8% due to incompliance, 3% due to sudden death and 8% due to other reasons. Dose modifications of ixazomib were required frequently (37% and 53% of patients during induction and maintenance, respectively), mainly due to, often low grade, polyneuropathy. During maintenance 23% of patients received daratumumab alone. Global quality of life (QoL) improved significantly and was clinically relevant, which persisted during maintenance treatment. Interpretation Ixazomib-Daratumumab-low-dose dexamethasone as first line treatment in intermediate -fit NDMM patients is safe and improves global QoL. However, efficacy was limited, partly explained by ixazomib-induced toxicity, hampering long term tolerability of this 3-drug regimen. This highlights the need for more efficacious and tolerable regimens improving the outcome in vulnerable intermediate -fit patients.

引用

页数：12

共 50 条

[21] Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial
Wester, Ruth
van der Holt, Bronno
Asselbergs, Emelie
van Duin, Mark
Zweegman, Sonja
Kersten, Marie Jose
Vellenga, Edo
Kooy, Marinus van Marwijk
de Weerdt, Okke
Minnema, Monique
Lonergan, Sarah
Palumbo, Antonio
Lokhorst, Henk M.
Broijl, Annemiek
Sonneveld, Pieter
BLOOD, 2016, 128 (22)
[22] Phase III trial of thalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma
不详
CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (07): : 452 - 453
[23] An open-label, prospective trial to evaluate the efficacy and safety of ixazomib in combination with cyclophosphamide and dexamethasone in patients with newly diagnosed POEMS syndrome
He, Haiyan
Hou, Nan
Chen, Xi
Song, Yaqi
Qiang, Wanting
Liu, Jin
Lu, Jing
Fu, Weijun
Du, Juan
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (02) : 478 - 482
[24] A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Isatuximab, Pomalidomide, and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed / Multiple Myeloma Refractory (RRMM)
Niederwieser, Dietger
Richardson, Paul
Attal, Michel
Rajkumar, Vincent
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulosu, Meletios
Huan, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Mace, Sandrine
Prince, H. Miles
Corzo, Kathryn P.
Campana, Frank
Le-Guennec, Solenn
Dubin, Franck
Anderson, Kenneth C.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 40 - 41
[25] KEYNOTE-185: A randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM)
Lonial, S.
de Oliveira, M. Ribeiro
Yimer, H.
Mateos, M. V.
Rifkin, R.
Schjesvold, F.
San-Miguel, J.
Ghori, R.
Marinello, P.
Jagannath, S.
ANNALS OF ONCOLOGY, 2016, 27
[26] KEYNOTE-185: a randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM).
Palumbo, Antonio
Mateos, Maria-Victoria
San Miguel, Jesus
Shah, Jatin
Thompson, Seth
Marinello, Patricia Maria
Jagannath, Sundar
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[27] Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma
Baz, Rachid C.
Shain, Kenneth H.
Hussein, Mohamad A.
Lee, Ji-Hyun
Sullivan, Daniel M.
Oliver, Elizabeth Finley
Nardelli, Lisa A.
Nodzon, Lisa A.
Zhao, Xiuhua
Ochoa-Bayona, Jose Leonel
Nishihori, Taiga
Dalton, William S.
Alsina, Melissa
AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (01) : 62 - 67
[28] AN OPEN-LABEL, PHASE 1B STUDY (MMY1001) OF DARATUMUMAB COMBINED WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)
Usmani, S. Z.
Chari, A.
Lonial, S.
Weiss, B.
Comenzo, R. L.
Wu, K.
Khokhar, N. Z.
Wang, J.
Doshi, P.
Jakubowiak, A.
HAEMATOLOGICA, 2017, 102 : 269 - 269
[29] Treatment of newly diagnosed, inner-city multiple myeloma patients with zoledronate, dexamethasone, and low-dose thalidomide: A phase II trial.
Klueppelberg, Uwe
Smith, Eric L. P.
Braunstein, Marc J.
Kahn, David
Batuman, Olcay A.
BLOOD, 2006, 108 (11) : 371B - 371B
[30] A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)
O'Donnell, Elizabeth K.
Suman, Vera Jean
Geyer, Susan M.
Nadeem, Omar
Dinner, Shira
Yee, Andrew J.
Laubach, Jacob P.
Mo, Clifton C.
Tuchman, Sascha A.
Donadio, Kristen
Sinclair, Sarah
Raje, Noopur S.
Richardson, Paul G.
BLOOD, 2021, 138

← 1 2 3 4 5 →